BiotechTube
Renasant Bio

Renasant Bio

Memphis, United States· Est.
renasantbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $54.5M

Overview

Renasant Bio is an early-stage, privately-held biotech focused on developing first-in-class, disease-modifying therapies for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company's strategy involves two complementary small molecule modalities: correctors to stabilize and properly traffic misfolded PC1/2 proteins, and potentiators to enhance the function of the polycystin ion channel. Backed by a $54.5 million Series A and a world-class team of scientific founders and advisors, the company is advancing a preclinical pipeline with the goal of providing a broadly effective oral treatment for a patient population with high unmet need. Its inclusion in BioSpace's NextGen Class of 2026 highlights its potential as an emerging company to watch.

NephrologyGenetic Disorders

Technology Platform

A small molecule platform featuring two modalities: correctors (pharmacological chaperones) to stabilize and restore trafficking of misfolded polycystin proteins (PC1/PC2), and potentiators to enhance the ion channel function of the PC1/PC2 complex, targeting the root cause of ADPKD.

Funding History

1
Total raised:$54.5M
PIPE$54.5M

Opportunities

The significant unmet need in ADPKD, with only one modestly effective therapy, creates a large market for a well-tolerated, oral disease-modifying drug.
The company's mutation-agnostic approach could address the vast majority of the genetically diverse patient population.
The commercial success of Vertex's corrector platform in cystic fibrosis provides a validated roadmap and investor confidence for this therapeutic strategy.

Risk Factors

High biological risk as novel, first-in-class mechanisms are unproven in humans and may fail in clinical trials.
The company is at an early, preclinical stage with no clinical data.
Intense competition from other biotechs and large pharma exploring diverse mechanisms for ADPKD treatment poses a threat.

Competitive Landscape

The competitive landscape includes Otsuka's tolvaptan (the only approved therapy) and several companies in earlier stages, such as Regulus Therapeutics (miRNA), Palladio Biosciences (vasopressin antagonist), and others exploring mTOR inhibitors, SGLT2 inhibitors, and gene therapy. Renasant Bio differentiates by directly targeting polycystin protein function with a dual small molecule approach, aiming for a more fundamental disease modification.

More companies in Small Molecule Drugs →More companies in United States →